Stock Evaluator: ProKidney Corp. (PROK)

ProKidney Corp. PROK

$1.04 -0.01 -0.48%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,708,501
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Commentary & Analysis


Financial Summary

Share Statistics PROK Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $217.0 $202.9 30%
Shares Out (Mil) 207.8 55.4 76%
Institutional Ownership 96.9% 92.9% 71%
Float (Mil) 185.2 40.7 72%
Beta 1.89 1.04 90%
Avg Daily Volume (000s) 1,179 566 71%
Price Change
(52-week)
(54.6%) 41.0% 18%
Growth PROK Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.2% na
Net Income (5yr) (20.9%) (10.3%) 19%
EPS (5yr) (15.1%) 15.8% 18
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) 22.0% (15.7%) 81%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 3 4
Current EPS ($0.180) ($0.649) ($0.626)
Month Ago EPS ($0.138) ($0.562) ($0.586)
# Rev Up 0 1 1
# Rev Down 1 0 0
Three Months Ago EPS ($0.138) ($0.562) ($0.586)
Year/Year Chg 5.3% 26.0% (2.9%)
Financials PROK Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $1 $39 2%
Net Income (TTM) (Mil) ($103) ($44) 11%
EPS (TTM) ($0.609) ($1.400) 25%
Operating Cash Flow (TTM) (Mil) ($153) ($34) 5%
Net Cash Flow (TTM) (Mil) ($14) ($1) 30%
Long-Term Debt (Q1) (Mil) $2 $4 20%
Enterprise Value (Q1) (Mil) $1,164 $144 43%
Valuation PROK Industry
Median
Percentile
(All Stocks)
P/B na 1.97 na
P/E na 17.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.8 na
Ratios PROK Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 67.6% 96%
Net Margin na (50.6%) na
ROA (36.8%) (47.4%) 14%
ROE 10.8% (53.5%) 59%
Liabilities to Assets 15.8% 29.7% 10%
F-Score 4 3 33%

ProKidney Corp. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors